Given the numbers of LSCs may provide prognostic value [5, 12], our findings support adding FLT3 (CD135) to current flow cytometric panels recommended for evaluation of ETP-ALL that could be extended to other T-ALL subtypes. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.